The French biotechnology company, which is pioneering an innovative approach targeting the tPA–NMDAr axis to treat neurodegenerative and neurovascular diseases, has reached a major milestone, securing more than €25 million in cumulative funding since its founding in 2021.
“Our ambition is to develop a new class of disease-modifying therapies for severe neurological diseases, including Parkinson’s disease, synucleinopathies such as multiple system atrophy, and ischaemic stroke,” says France’s Lys Therapeutics.
The funding will be used to complete regulatory studies, secure large-scale manufacturing and support LYS241’s entry into clinical development through a biomarker-rich Phase 1a/1b programme, incorporating indication-specific cohorts across several neurological diseases.
These supporters include the Michael J. Fox Foundation for Parkinson’s Research, a U.S.-based foundation that recently awarded Lys Therapeutics a grant of more than $5 million to accelerate the clinical development of LYS241 in Parkinson’s disease.
This momentum is also supported by several selective public programs backing breakthrough healthcare innovation, including Bpifrance and France 2030.
This growth momentum is accompanied by the arrival of new strategic investors in the company’s share capital: Normandie Participation, the investment fund of the Normandy Region, TCD Capital (The Club Deal), an investment fund backed by European private investors, as well as FIDAT Ventures, the Oddo family investment vehicle.
They join Lys Therapeutics’ historical investors, including ZCUBE, the investment vehicle of the pharmaceutical group Zambon, as well as Philippe Bissay, Chairman and Chief Executive Officer of HAC Pharma.
Raising more than €25 million in only five years is a strong recognition of the quality of our science, the relevance of our therapeutic approach and the broad potential of LYS241. This financial support gives us the means to pursue the regulatory studies and finalize preparation of a Phase 1a/1b clinical program. The recent advances achieved in Parkinson’s disease, synucleinopathies and ischemic stroke reinforce our conviction that LYS241 can become a cross-indication therapeutic platform for several severe neurological diseases. Our ambition is to translate differentiated biology into a new class of treatments capable of modifying the course of diseases for which medical needs remain considerable.
Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics
About Lys Therapeutics
Lys Therapeutics is an advanced preclinical-stage biotechnology companydeveloping innovative monoclonal antibodies to treat patients with severe neurodegenerative and neurovascular diseases associated with significant unmet medical needs. The company targets upstream biological determinants, shared across several major neurological indications, at the intersection of neurovascular dysfunction, neuroinflammation and excitotoxicity.
Photo: Dr. Manuel Blanc, CEO and co-founder of Lys Therapeutics
02.07.2026.
